Calamos Advisors’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RPRX
Calamos Advisors's RPRX Position: Q2 2026 in Review
Calamos Advisors increased its Royalty Pharma (RPRX) stake by 31% in Q2 2026, buying an estimated $7.1M and bringing the position to 573,521 shares worth $32.2M. The position accounts for 0.11% of the portfolio, ranked #192.
Calamos Advisors first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.
- Calamos Advisors held 573,521 shares of Royalty Pharma worth $32.2M as of Q2 2026.
- Calamos Advisors bought 136,431 Royalty Pharma shares in Q2 2026, an estimated $7.1M.
- Royalty Pharma made up 0.11% of Calamos Advisors's portfolio in Q2 2026, its #192 holding.
- Calamos Advisors first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
- 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.
Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.